Dietary Amino Acids and the Gut‐Microbiome‐Immune Axis: Physiological Metabolism and Therapeutic Prospects
Top Cited Papers
Open Access
- 18 December 2018
- journal article
- review article
- Published by Wiley in Comprehensive Reviews in Food Science and Food Safety
- Vol. 18 (1), 221-242
- https://doi.org/10.1111/1541-4337.12401
Abstract
Dietary amino acids (AAs) are not only absorbed and metabolized by enterocytes but also available to the microbiota in the gut in mammals. In addition to serving as the materials for protein synthesis, AAs can act as precursors for numerous metabolic end products in reactions involving the intestinal mucosa and microbiota. After penetrating the epithelial barrier, microbial metabolites can enter and accumulate in the host circulatory system, where they are sensed by immune cells and then elicit a wide range of biological functions via different receptors and mechanisms. Some intestinal bacteria can also synthesize certain AAs, implying that the exchange of AAs between hosts and microorganisms is bidirectional. Changes in AA composition and abundance can affect AA‐metabolizing bacterial communities and modulate macrophages and dendritic cells via toll‐like receptors (TLRs), autoinducer‐2 (AI‐2), and NOD‐like receptors (NLRs), and also regulate the gut‐microbiome‐immune axis via aryl hydrocarbon receptor (AhR), serotonin/5‐hydroxytryptamine (5‐HT), and other signaling pathways, all of which play critical roles in regulating the intestinal mucosal immunity and microbiota directly or indirectly, contributing to intestinal homeostasis. Therefore, the current findings of the effects of certain functional AAs on the gut‐microbiome‐immune axis are reviewed, illustrating signaling pathways of tryptophan (Trp), glutamine (Gln), methionine (Met), and branched‐chain AAs (BCAAs) in the intestinal barrier and regarding immunity via crosstalk with their receptors or ligands. These findings have shed light on the clinical applications of dietary AAs in improving gut microbiota and mucosal immunity, therefore benefiting the gut as well as local and systemic health.Keywords
Funding Information
- National Natural Science Foundation of China (31472101, 31722054, 31829004)
This publication has 189 references indexed in Scilit:
- The gut microbiota regulates bone mass in miceJournal of Bone and Mineral Research, 2012
- AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of NotchNature Immunology, 2011
- Therapeutics of 5-HT3 receptor antagonists: Current uses and future directionsPharmacology & Therapeutics, 2011
- Toll-like receptors in inflammatory bowel diseases: A decade laterInflammatory Bowel Diseases, 2010
- Nod2 is required for the regulation of commensal microbiota in the intestineProceedings of the National Academy of Sciences of the United States of America, 2009
- Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficitsNature, 2008
- 16S ribosomal RNA-based methods to monitor changes in the hindgut bacterial community of piglets after oral administration of Lactobacillus sobrius S1Anaerobe, 2008
- Probiotic modulation of symbiotic gut microbial–host metabolic interactions in a humanized microbiome mouse modelMolecular Systems Biology, 2008
- Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypesMolecular Systems Biology, 2008
- Toll-like receptor signallingNature Reviews Immunology, 2004